While CAR-T therapies could vastly improve outcomes in some types of blood cancer, finding ways to replicate this effectively and safely in solid tumours remains a challenge.
Swiss pharma giant Novartis saw modest growth of 2% in 2017, with growth in Cosentyx and Entresto offsetting generic erosion to its cancer blockbuster Gleevec/Glivec.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.